Your session is about to expire
← Back to Search
MR-Guided Prostate SBRT for Prostate Cancer (PRAGMA Trial)
PRAGMA Trial Summary
This trial finds that MRI-guided prostate SBRT is safe for patients with metastatic prostate cancer, with similar quality of life outcomes to those without metastatic prostate cancer.
- Hormone-Refractory Prostate Cancer
PRAGMA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PRAGMA Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this clinical experiment require additional participants?
"Affirmative. Clinicaltrials.gov confirms that this research is actively searching for participants and has been since January 27th 2020. 20 individuals are required from a single trial site, with the most recent update on April 10th 2022."
How many participants will be included in this research endeavor?
"Affirmative, the data from clinicaltrials.gov reveals that this medical trial is in the process of enrolling participants. This study was first shared on January 27th 2020 and last updated April 10th 2022; with a target of 20 patients at one site."
Are elderly individuals aged 75 and over able to partake in this medical experiment?
"As dictated by the protocols of this medical trial, prospective participants must be aged 18 or older but no more than 90."
May I be considered for enrollment in this scientific inquiry?
"Researchers are recruiting up to 20 individuals with prostate cancer, aged 18-90. Notably, applicants must demonstrate a biopsy diagnosis of adenocarcinoma and fulfill the minimum age requirement."
Has this remedy received authorization from the FDA?
"This treatment has been seen to possess some clinical efficacy and rudimentary safety data, so it was given a rating of 1 on our team's scale."
Share this study with friends
Copy Link
Messenger